CClinicalTrials.gg
Active, not recruitingNCT07593768Updated May 18, 2026

Clinical and Prognostic Significance of Periodontitis in Patients With Arterial Hypertension

An observational study in Arterial Hypertension and Periodontitis, sponsored by I.M. Sechenov First Moscow State Medical University. Active, not recruiting at 1 site in Russia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by I.M. Sechenov First Moscow State Medical University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

As part of a prospective study, to evaluate the effect of periodontitis on the course of hypertension at baseline, during 6 and 12 months

Read the detailed description

The study focuses on following tasks: to evaluate and compare arterial stiffness in patients with hypertension and the control group, the effect of treatment and control of clinical manifestations of periodontitis in patients with hypertension and the control group, the effect of treatment and control of clinical manifestations of periodontitis on the level of CRP in patients with hypertension and the control group, the effect of periodontitis control on the dynamics of OH, LDL, TG, uric acid, and fasting glycemia levels, the effect of periodontitis on the risk of atrial fibrillation/flutter in patients with arterial hypertension, to develop an information platform for patients with periodontitis for early detection of CVD risks and control of modifiable risk factors

02

Conditions studied

  • Arterial Hypertension
  • Periodontitis

Keywords

  • cardiovascular risk
  • arterial hypertension
  • inflammation
  • periodontitis
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's planned enrollment of 200 is close to the median of 210 across 1,359 observational studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

I.M. Sechenov First Moscow State Medical University is the lead sponsor of 133 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study is set to include 200 patients (both sexes) over 18 years of age with arterial hypertension who signed the informed consent form for participation in the study: 100 patients with periodontitis and 100 patients without periodontitis - control group

Inclusion criteria

  • Age (18 years and older)
  • Written informed consent signed

Exclusion criteria

Exclusion Criteria:

  • Failure to follow up
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Periodontitis group

    Diagnostic Test: Orthopantomography

  • Control group

    Diagnostic Test: Orthopantomography

Interventions

  • Diagnostic testOrthopantomography

    Orthopantomography

06

What researchers measure

Primary outcomes

  1. Triglyceride level

    Triglyceride level

    Time frame: 12 months from inclusion

  2. Low density lipoprotein level

    Low density lipoprotein level

    Time frame: 12 months from inclusion

07

Study locations

1 site
  • University hospital #1
    Moscow, Russia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07593768
Lead sponsor
I.M. Sechenov First Moscow State Medical University
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Oct 10, 2023
Primary completion
Sep 1, 2025
Completion
May 30, 2026 (estimated)
Last update
May 18, 2026

Study contacts

Olga Trushina, MD, PhD
principal investigator · Sechenov University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion